AZ12216052

AZD1222 is a viral vector vaccine for COVID-19. It was developed by Oxford University and AstraZeneca, and is known by the brand names Vaxzevria and Covishield.

Development and Testing

The vaccine was developed by the Jenner Institute and the Oxford Vaccine Group. The first phase of testing began in April 2020, with the second and third phases following in May and August respectively. The vaccine uses a modified adenovirus that contains a gene from the SARS-CoV-2 virus.

Efficacy

The efficacy of AZD1222 has been found to be approximately 70%, although this can vary depending on the dosage and the interval between doses. The vaccine has been shown to be effective against severe disease and hospitalisation.

Side Effects

Common side effects of AZD1222 include pain and swelling at the injection site, fatigue, headache, muscle pain, chills, fever, and nausea. Rare but serious side effects include blood clots and anaphylaxis.

Distribution and Administration

AZD1222 is administered in two doses, with a recommended interval of 4 to 12 weeks between doses. It has been approved for emergency use in many countries, and is part of the COVAX initiative to ensure equitable access to COVID-19 vaccines.

See Also

• COVID-19 vaccine
• COVID-19 pandemic
• AstraZeneca
• Oxford University

‎

‎